1.
CTHRC1 is associated with BRAF(V600E) mutation and correlates with prognosis, immune cell infiltration, and drug resistance in colon cancer, thyroid cancer, and melanoma. Biomol Biomed [Internet]. 2024 Dec. 11 [cited 2025 Feb. 6];25(1):42–61. Available from: https://bjbms.org/ojs/index.php/bjbms/article/view/10397